Two Milestone Studies in Liver Cancer Immunotherapy
Tim F Greten1,2, Cecilia Monge1
1Gastrointestinal Malignancies Section, Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Institutes of Health, National Cancer Institute, Bethesda, MD.
Abstract:
Immunotherapy has changed the playing field for multiple cancers, and prime time for unresectable liver cancers may be here now. This issue of NEJM Evidence includes two trials describing novel immunotherapy options for patients with biliary tract cancer and hepatocellular carcinoma. Oh et al.1 describe the results of the TOPAZ-1 trial, which resulted in improved overall survival for patients with biliary tract cancer in the frontline setting - the first real advance in more than a decade.2 Abou-Alfa et al.3 present results from the HIMALAYA study.
More Related Videos
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
